Vanguard Global Advisers
PDSB icon

Vanguard Global Advisers’s PDS Biotechnology PDSB Stock Holding History

Vanguard Global Advisers’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1K Hold
12,546
– – ﹤0.01% 3465
2026
Q1 		$7.59K Buy
+12,546
New +$9.44K ﹤0.01% 3509

Other funds holding PDSB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Vanguard Global Advisers's PDSB Position: Q2 2026 in Review

Vanguard Global Advisers held its PDS Biotechnology (PDSB) position steady in Q2 2026 at 12,546 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3465.

Vanguard Global Advisers first reported a position in PDSB in Q1 2026 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

  • Vanguard Global Advisers held 12,546 shares of PDS Biotechnology worth $11.1K as of Q2 2026.
  • Vanguard Global Advisers left its PDS Biotechnology share count unchanged in Q2 2026.
  • PDS Biotechnology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3465 holding.
  • Vanguard Global Advisers first reported a position in PDS Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.